PMID: 2507218May 1, 1989Paper

In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use

Diagnostic Microbiology and Infectious Disease
R N Jones, A L Barry

Abstract

Ramoplanin, a new depsipeptide complex, was found to be 4- to 8-fold more active than vancomycin against all Gram-positive species (500 strains). Similarly, ramoplanin was both more active and had an additional spectrum compared to mupirocin (formerly pseudomonic acid) against Bacillus spp., Corynebacterium jeikeium, enterococci and Listeria monocytogenes. Mupirocin-resistant Staphylococcus spp. strains (less than 1%) were identified in these organisms collected from over 40 medical centers in the United States. These strains (S. capitis and S. saprophyticus) were susceptible to ramoplanin at 0.25 micrograms/ml or less. The three tested antimicrobial agents were not effective against Gram-negative organisms (20 species tested). Ramoplanin was bactericidal and MICs were not adversely influenced by high (greater than or equal to 10(7) CFU/ml) inoculum concentrations. Because ramoplanin has previously shown promise as a topical drug, these in vitro results further substantiate its wide spectrum, potency, and potential clinical usefulness as mupirocin-resistant staphylococci and other Gram-positive species become more prevalent.

References

Feb 1, 1989·Antimicrobial Agents and Chemotherapy·J O CapobiancoR C Goldman
Jan 1, 1988·The Journal of Antimicrobial Chemotherapy·G E Smith, C T Kennedy
Nov 1, 1988·The Journal of Antimicrobial Chemotherapy·W C NobleI Phillips
Dec 1, 1988·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S DixsonJ M Hamilton-Miller
Jan 1, 1986·Chemotherapy·H C Neu, N M Neu
Apr 1, 1985·Antimicrobial Agents and Chemotherapy·R SutherlandA R White
Oct 1, 1984·Antimicrobial Agents and Chemotherapy·R PallanzaV Arioli
Nov 1, 1980·Antimicrobial Agents and Chemotherapy·R D PearsonS W Chapman

❮ Previous
Next ❯

Citations

Jun 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A BarryJ McLaughlin
Jul 1, 1989·Diagnostic Microbiology and Infectious Disease·R N Jones
Oct 1, 1993·Diagnostic Microbiology and Infectious Disease·R ScottiB P Goldstein
Feb 1, 1994·Diagnostic Microbiology and Infectious Disease·M T KennyJ K Dulworth
Jun 27, 2007·Journal of the American Chemical Society·Joonwoo NamDale L Boger
Oct 1, 1992·Antimicrobial Agents and Chemotherapy·C C JohnsonM E Levison
Jun 1, 1993·Antimicrobial Agents and Chemotherapy·L A CollinsR C Moellering
Oct 1, 1995·The American Journal of Medicine·K V RolstonG P Bodey
Jul 28, 2010·FEMS Microbiology Letters·John W SchmidtDewey G McCafferty
Dec 20, 2002·Biopolymers·Dewey G McCaffertyWenkai Li
Oct 1, 1995·Clinical Microbiology Reviews·N WoodfordD C Speller
Jul 1, 1993·Journal of Clinical Microbiology·A L BarryP C Fuchs
Feb 13, 2003·Journal of the American Chemical Society·Wanlong JiangDale L Boger
May 9, 2002·Journal of the American Chemical Society·Wanlong JiangDale L Boger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Antimicrobial Agents and Chemotherapy
E A Somner, P E Reynolds
The Journal of Pediatrics
R A BRIDGESR A GOOD
A.M.A. Archives of Internal Medicine
W M KIRBYW D NOYES
© 2022 Meta ULC. All rights reserved